Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_assertion type Assertion NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_head.
- NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_assertion wasGeneratedBy ECO_0000203 NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_provenance.
- NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_assertion wasDerivedFrom befree-20140225 NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_provenance.
- NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_assertion SIO_000772 12646934 NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_provenance.
- NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_assertion evidence source_evidence_literature NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_provenance.
- NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_assertion description "[Imatinib mesylate, an Abl-specific kinase inhibitor, produces sustained complete hematologic responses (CHR) and major cytogenetic responses (MCR) in chronic myeloid leukemia (CML) patients, but long-term outcomes in these patients are not yet known.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP809063.RAryU4gBqTBrwUcBVTH4GeSKZ1Ty5_iBMiMJ7IpBc22F0130_provenance.